Jazz Pharmaceuticals IPO Will Fund Luvox CR Commercialization

Jazz Pharmaceuticals is hoping to raise more than $100 million through its initial public offering to help fund the commercialization of its lead compound, Luvox CR (see chart: "1Jazz Pharmaceuticals IPO")